Compare Adaptive Biotechnologies Corp (ADPT) vs Walt Disney Co (DIS) Price & Performance

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

Disney (DIS) trades at $96.70, down 0.73% with bearish technical signals despite strong fundamentals. The company shows robust revenue growth to $94.43B in 2025 and consistent earnings beats, with Q2 2026 EPS expected at $1.88. Analyst consensus remains strongly bullish with a $131.89 price target, though recent news highlights challenges including a $4.2B Paris parks deficit and Star Wars box office underperformance.

Disney presents a compelling value opportunity with attractive valuation ratios (P/E 15.6, P/S 1.8) and strong cash flow generation ($18.1B operating cash flow). Key risks include theme park profitability concerns, streaming competition, and regulatory challenges with the FCC. The stock offers 36% upside to consensus targets if execution improves.